NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
Ian Sarembock, MD - is a retired Coronary & Structural Interventionalist and was previously the Harold C. Schott Endowed Chair in Structural Heart at...
Neobe Therapeutics is an early-stage startup engineering safe recombinant bacterial products to enable immune infiltration in solid tumors. Their bacterial products combine innate tumor...
Ai Medica makes it easy to create clinical and economic value from EHR data using evidence based medicine. They have built a platform on...
